Heartflow (NASDAQ:HTFL) Director Julie Cullivan Sells 9,122 Shares

Heartflow, Inc. (NASDAQ:HTFL) Director Julie Cullivan sold 9,122 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $25.00, for a total transaction of $228,050.00. Following the transaction, the director owned 27,291 shares of the company’s stock, valued at $682,275. This trade represents a 25.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Heartflow Stock Performance

Shares of HTFL opened at $22.98 on Friday. The stock has a market capitalization of $1.96 billion and a PE ratio of -12.70. The company has a 50 day moving average price of $28.43 and a 200-day moving average price of $30.96. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $41.22.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Wells Fargo & Company assumed coverage on shares of Heartflow in a report on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 price objective for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Stifel Nicolaus increased their price objective on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, Canaccord Genuity Group upped their target price on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Heartflow currently has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Wellington Management Group LLP grew its holdings in Heartflow by 20.8% in the fourth quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock valued at $171,812,000 after purchasing an additional 1,014,006 shares during the period. Baillie Gifford & Co. bought a new position in shares of Heartflow in the third quarter valued at approximately $101,182,000. Bamco Inc. NY raised its holdings in Heartflow by 86.2% during the fourth quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock worth $67,158,000 after purchasing an additional 1,066,371 shares in the last quarter. Schusterman Interests LLC bought a new stake in shares of Heartflow in the 3rd quarter worth $65,274,000. Finally, Capricorn Investment Group LLC bought a new position in Heartflow during the fourth quarter valued at about $48,178,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.